FDA Inspection 1231637 — Oklahoma Blood Institute

Oklahoma Blood Institute — FEI 1626009

The FDA completed an inspection of Oklahoma Blood Institute on August 20, 2024 in Oklahoma City, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
August 20, 2024
Fiscal Year
2024
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Oklahoma City, OK (United States)